Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940781171> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2940781171 abstract "Background Malaria remains a public health problem in sub-Saharan Africa, especially amongst children and pregnant women. Artemisinin-based combination therapy (ACT) is now the treatment of choice. Adverse drug reactions (ADR) have been observed to ACTs. This study aims to determine the incidence, pattern of presentation and factors associated with ADRs to artemether-lumefantrine (AL) and artemisinin-piperaquine (AP) among children with acute uncomplicated malaria in Ibadan, Nigeria. Methods Children aged 2–10 years with acute uncomplicated malaria who met the inclusion criteria, were enrolled, randomised to receive one of the study drugs (AL or AP) and followed up for 28 days. Monitoring for ADR was based on history from the parent/guardian and/or child regarding occurrences of treatment emergent signs and symptoms and on abnormalities of laboratory investigations (full blood count and blood chemistry). Causality assessment for the ADR was by the Naranjo algorithm scale while the severity was assessed using the Hartwig’s severity scale. Results A total of 114 children were enrolled; six defaulted and were not available for follow-up. There were 61 (56.5%) males. The mean age of enrollees was 65.1±30.0 months. Fever was the most prevalent presenting complaint occurring in 108 (100%) enrollees. Observed ADRs were cough, diarrhoea, loss of appetite, abdominal pain, rash, fever, irritability, insomnia and headache but the differences were not statistically significant between the two groups. The incidence of ADR to both ACTs was 12/1000 patients per day. Prevalence of ADR to AL was 14% and for AP 11%; this was not statistically significant. All ADRs were mild. No notable associated factor to ADR was detected in this study. Conclusion Both AL and AP were found to be safe in the study population." @default.
- W2940781171 created "2019-05-03" @default.
- W2940781171 creator A5038575237 @default.
- W2940781171 creator A5078483356 @default.
- W2940781171 date "2019-04-01" @default.
- W2940781171 modified "2023-09-24" @default.
- W2940781171 title "PO 8448 ADVERSE DRUG REACTION TO TWO ARTEMISININ-BASED COMBINATION THERAPIES, ARTEMETHER-LUMEFANTRINE AND ARTEMISININ-PIPERAQUINE, IN CHILDREN WITH ACUTE UNCOMPLICATED MALARIA IN IBADAN, NIGERIA" @default.
- W2940781171 doi "https://doi.org/10.1136/bmjgh-2019-edc.102" @default.
- W2940781171 hasPublicationYear "2019" @default.
- W2940781171 type Work @default.
- W2940781171 sameAs 2940781171 @default.
- W2940781171 citedByCount "0" @default.
- W2940781171 crossrefType "journal-article" @default.
- W2940781171 hasAuthorship W2940781171A5038575237 @default.
- W2940781171 hasAuthorship W2940781171A5078483356 @default.
- W2940781171 hasBestOaLocation W29407811711 @default.
- W2940781171 hasConcept C120665830 @default.
- W2940781171 hasConcept C121332964 @default.
- W2940781171 hasConcept C126322002 @default.
- W2940781171 hasConcept C187212893 @default.
- W2940781171 hasConcept C197934379 @default.
- W2940781171 hasConcept C203014093 @default.
- W2940781171 hasConcept C2776120307 @default.
- W2940781171 hasConcept C2777199930 @default.
- W2940781171 hasConcept C2777425658 @default.
- W2940781171 hasConcept C2778048844 @default.
- W2940781171 hasConcept C2778118209 @default.
- W2940781171 hasConcept C2778371730 @default.
- W2940781171 hasConcept C2778570526 @default.
- W2940781171 hasConcept C2780780316 @default.
- W2940781171 hasConcept C61511704 @default.
- W2940781171 hasConcept C71924100 @default.
- W2940781171 hasConceptScore W2940781171C120665830 @default.
- W2940781171 hasConceptScore W2940781171C121332964 @default.
- W2940781171 hasConceptScore W2940781171C126322002 @default.
- W2940781171 hasConceptScore W2940781171C187212893 @default.
- W2940781171 hasConceptScore W2940781171C197934379 @default.
- W2940781171 hasConceptScore W2940781171C203014093 @default.
- W2940781171 hasConceptScore W2940781171C2776120307 @default.
- W2940781171 hasConceptScore W2940781171C2777199930 @default.
- W2940781171 hasConceptScore W2940781171C2777425658 @default.
- W2940781171 hasConceptScore W2940781171C2778048844 @default.
- W2940781171 hasConceptScore W2940781171C2778118209 @default.
- W2940781171 hasConceptScore W2940781171C2778371730 @default.
- W2940781171 hasConceptScore W2940781171C2778570526 @default.
- W2940781171 hasConceptScore W2940781171C2780780316 @default.
- W2940781171 hasConceptScore W2940781171C61511704 @default.
- W2940781171 hasConceptScore W2940781171C71924100 @default.
- W2940781171 hasLocation W29407811711 @default.
- W2940781171 hasOpenAccess W2940781171 @default.
- W2940781171 hasPrimaryLocation W29407811711 @default.
- W2940781171 hasRelatedWork W1968329346 @default.
- W2940781171 hasRelatedWork W2028323532 @default.
- W2940781171 hasRelatedWork W2047269575 @default.
- W2940781171 hasRelatedWork W2075267721 @default.
- W2940781171 hasRelatedWork W2151344802 @default.
- W2940781171 hasRelatedWork W2152960683 @default.
- W2940781171 hasRelatedWork W2262927268 @default.
- W2940781171 hasRelatedWork W2271097490 @default.
- W2940781171 hasRelatedWork W2298359671 @default.
- W2940781171 hasRelatedWork W2561548234 @default.
- W2940781171 hasRelatedWork W2585286825 @default.
- W2940781171 hasRelatedWork W2588194639 @default.
- W2940781171 hasRelatedWork W2790471917 @default.
- W2940781171 hasRelatedWork W2799524882 @default.
- W2940781171 hasRelatedWork W2917926651 @default.
- W2940781171 hasRelatedWork W2947473331 @default.
- W2940781171 hasRelatedWork W3081821124 @default.
- W2940781171 hasRelatedWork W3186717474 @default.
- W2940781171 hasRelatedWork W3188603079 @default.
- W2940781171 hasRelatedWork W2610931659 @default.
- W2940781171 isParatext "false" @default.
- W2940781171 isRetracted "false" @default.
- W2940781171 magId "2940781171" @default.
- W2940781171 workType "article" @default.